Search

Displaying results 591 - 600 of 4539 in total
  1. Drug

    Beclomethasone dipropionate

    go.drugbank.com/drugs/DB00394
    ApprovedInvestigational

    Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to dexamethasone. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) ...

    Mixtures: FOSTER 100/6 UG 120 HUB, FOSTER 100/6 UG 120 HUBProducts: BECLOMET EASY0.1MG200ED SK, BECLOMET EASY0.2MG200ED SK
  2. Drug

    Pentetic acid

    go.drugbank.com/drugs/DB14007
    ApprovedInvestigational

    [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469] … DTPA, along with its calcium and zinc trisodium salts, are the only FDA approved agents for the treatment of internal contamination by transuranics.

  3. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    [A32025] About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. … Commonly marketed under the trade name Wakix, oral pitolisant was approved by the EMA in 2016 [A183062] for the treatment of narcolepsy with or without cataplexy.

  4. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation

  5. Drug

    Ferrous sulfate anhydrous

    go.drugbank.com/drugs/DB13257
    ApprovedInvestigational

    It is the gold standard of oral iron therapy in the UK and many other countries.[L2234,L2246]

  6. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]

  7. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other … Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A).

  8. Drug

    Chikungunya virus Senegal strain 37997 envelope protein E1

    go.drugbank.com/drugs/DB21767
    ApprovedInvestigational

    One of three components of a recombinant Chikungunya virus vaccine called Vimkunya.

  9. Drug

    Benralizumab

    go.drugbank.com/drugs/DB12023
    ApprovedInvestigational

    [A31293] Benralizumab was FDA approved on November 14, 2017, and was developed by MedImmune, AstraZeneca's global biologic research and development arm.[L1019]

  10. Drug

    Spesolimab

    go.drugbank.com/drugs/DB15626
    ApprovedInvestigational

    It is a humanized monoclonal immunoglobulin G1 antibody that was produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology. … The biosimilar of the drug, spesolimab-sbzo, was first approved by the FDA in September 2022 to treat generalized pustular psoriasis flares.